In adults with type 2 diabetes at high cardiovascular risk, semaglutide lowered the rate of the primary composite cardiovascular outcome versus placebo, confirming noninferiority.
In plain wordsIn adults with type 2 diabetes at high heart risk, fewer people on semaglutide than on placebo had a heart attack, stroke or heart-related death.
- Peptide
- Semaglutide
- Outcome
- DecreaseFirst cardiovascular death, nonfatal myocardial infarction or nonfatal stroke
- Study
n = 3,297
- Comparator
- Placebo
- Analysis
- Primary
- Outcome group
- Cardiovascular events · Cardiovascular
- Studied dose
- 0.5 mg or 1.0 mg once weekly · 104 weeksAs given in this study (human).
Measurements
- Hazard ratio
- 0.74 ratio
- primary outcome, semaglutide vs placebo
Source sentences
The primary outcome occurred in 108 of 1648 patients (6.6%) in the semaglutide group and in 146 of 1649 patients (8.9%) in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.58 to 0.95; P<0.001 for noninferiority).
1 context sentence(design, population, supporting numbers)
We randomly assigned 3297 patients with type 2 diabetes who were on a standard-care regimen to receive once-weekly semaglutide (0.5 mg or 1.0 mg) or placebo for 104 weeks.